AbbVie and Sandoz Resolve Patent Dispute Over Rinvoq Generics Settlement

AbbVie Inc. has reached a settlement in its legal dispute with Sandoz Inc. over allegations of patent infringement related to Sandoz’s proposed generic versions of AbbVie’s significant immunosuppressant drug, Rinvoq. The details of the settlement were outlined in a stipulation submitted to the Delaware federal court on Friday. This agreement ends the clash over intellectual property rights concerning formulations and patents tied to the drug, which is a prominent part of AbbVie’s product lineup. For additional details regarding the settlement terms, the original court filing can be accessed through Law360.